Search Results

Collegium Pharmaceutical, Inc. today announced it has entered into an authorized generic agreement with Hikma Pharmaceuticals USA Inc. (“Hikma”), pursuant to which Hikma will have the exclusive right to sell the authorized generic versions of Nucynta® and Nucynta ® ER.

Despite a patent extension, Merck’s muscle relaxant reversal injection is now facing potential generic competition from Hikma Pharmaceuticals, which is seeking the FDA’s approval for a copycat version.

CanariaBio Inc. and Hikma MENA FZE, part of Hikma Pharmaceuticals PLC, announced the signing of distribution and license agreement for oregovomab in the Middle East and North Africa region.

Guardant Health, Inc. and Hikma Pharmaceuticals PLC announced an agreement to promote Guardant Health’s portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumor mutation profiling across all solid cancers in countries across the Middle East and North Africa.

Corcept Therapeutics Incorporated today announced that it has entered into an agreement with Hikma Pharmaceuticals USA Inc. (“Hikma”) resolving patent litigation related to Korlym ®, Corcept’s medication for the treatment of patients with Cushing’s syndrome.

Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox™ platform announces an exclusive licensing and commercialization agreement with Hikma Pharmaceuticals PLC, a multinational pharmaceutical company for the Middle East and North Africa.

Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary to a PR Newswire announcement issued today indicating that Opiant Pharmaceuticals and Hikma have entered into a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK.